Cellectar Biosciences (NASDAQ:CLRB) Stock Price Crosses Below 200 Day Moving Average of $3.30

Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.30 and traded as low as $2.30. Cellectar Biosciences shares last traded at $2.37, with a volume of 548,187 shares traded.

Cellectar Biosciences Stock Down 3.2 %

The company has a market cap of $82.10 million, a P/E ratio of -0.74 and a beta of 0.98. The company’s 50-day moving average is $2.80 and its two-hundred day moving average is $3.29.

Cellectar Biosciences (NASDAQ:CLRB) last posted its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. On average, analysts anticipate that Cellectar Biosciences, Inc. will post -1.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Cellectar Biosciences by 2.3% during the third quarter. Vanguard Group Inc. now owns 175,884 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 3,911 shares in the last quarter. Worth Venture Partners LLC grew its position in shares of Cellectar Biosciences by 148.6% during the 4th quarter. Worth Venture Partners LLC now owns 693,909 shares of the biopharmaceutical company’s stock valued at $1,922,000 after purchasing an additional 414,786 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Cellectar Biosciences in the fourth quarter worth $3,817,000. AIGH Capital Management LLC raised its position in shares of Cellectar Biosciences by 182.7% in the fourth quarter. AIGH Capital Management LLC now owns 1,915,220 shares of the biopharmaceutical company’s stock worth $5,305,000 after buying an additional 1,237,709 shares in the last quarter. Finally, Rosalind Advisors Inc. boosted its stake in Cellectar Biosciences by 335.4% during the second quarter. Rosalind Advisors Inc. now owns 2,705,616 shares of the biopharmaceutical company’s stock valued at $6,764,000 after buying an additional 2,084,138 shares during the period. 16.41% of the stock is currently owned by hedge funds and other institutional investors.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.